Genpharmasec Fund Raise of ₹48.45 Cr

Genpharmasec Management Change

Genpharmasec's Company Secretary and Compliance Officer Hardik Makwana resigned, effective 16 November 2026. The resignation reflects a senior key managerial personnel departure, citing other professional opportunities.

Genpharmasec Financial Results

Genpharmasec approved unaudited half-year results and planned sale of its wholly owned subsidiary Clinigenome India. Company Secretary Hardik Makwana resigns effective 16 November 2026.

Genpharmasec Board Meeting Date

Genpharmasec Ltd will hold a Board meeting on 03 Nov 2026. Agenda includes proposing approval of Q2/H1 FY27 unaudited results.

Genpharmasec Other Announcement

Genpharmasec Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing provides a standard breakdown of promoter and public shareholding.

Genpharmasec Annual General Meeting

Genpharmasec Limited conducted its 34th Annual General Meeting on September 29, 2026. Shareholders considered resolutions including the adoption of FY26 financial statements and director re-appointments.

Genpharmasec Annual Report

Genpharmasec Ltd filed its 34th Annual Report for FY 2025-26 with BSE, including the AGM notice for 29 September 2026. The report covers audited financials, board updates, and governance disclosures.

Om Metallogic Fund Raise

Om Metallogic Ltd intimated a board meeting on 14 November 2026 to approve rights issue issue price, entitlement ratio, record date and issue dates. The rights issue follows BSE in-principle approval.

Virinchi Fund Raise of ₹30 Cr

Virinchi's board approved a Rs 30 Crore preferential issue of 2 crore convertible warrants at Rs 15 each. Subject to EGM approval, allottees include promoter Viswanath Kompella.

Value

₹30.00 Cr

Execution

Warrant tenure not exceeding 18 months from allotment

IIFL Finance Fund Raise of ₹6,414 Cr

IIFL Finance's board approved a preferential issue of convertible preference shares and warrants worth Rs.6,414.20 Crore. Shareholder approval is needed at a 4 December EGM.

Value

₹6,414 Cr

Bajaj Finance Fund Raise of ₹5,800 Cr

Bajaj Finance's special committee approved issuing 5.74 crore warrants to promoter Bajaj Finserv at ₹1,010 each. The issue raises about ₹5,800 crore.

Value

₹5,800 Cr

Cholamandalam Investment & Finance Company Fund Raise of ₹5,000 Cr

Cholamandalam Investment sent shareholders a postal ballot notice seeking approval for a Rs 5,000 crore QIP. E-voting runs November 10 to December 9, 2026.

Value

₹5,000 Cr

Execution

Allotment to be completed within 365 days of shareholder approval

HB Leasing & Finance Co Fund Raise

HB Leasing's board discussed fund-raising options on November 9, 2026, including equity and preference shares. No quantum or pricing is decided; advisers will be consulted.